OCUGEN, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
OCUGEN, INC. (OCGN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $16.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-04
- OCUGEN, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $16.40M, a 127.78% increase from fiscal 2024.
- OCUGEN, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $7.20M, a 56.89% decline from fiscal 2023.
- OCUGEN, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $16.70M, a 11.33% increase from fiscal 2022.
- OCUGEN, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $15.00M, a 19.35% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $16.40M 10-K · filed 2026-03-04 | |
| 2024-12-31 | $7.20M 10-K · filed 2025-03-05 | |
| 2023-12-31 | $16.70M 10-K · filed 2024-04-16 | |
| 2022-12-31 | $15.00M 10-K · filed 2023-02-28 | |
| 2021-12-31 | $18.60M 10-K · filed 2022-02-28 | |
| 2020-12-31 | $6.90M 10-K · filed 2021-03-19 | |
| 2019-12-31 | $44.80M 10-K · filed 2020-03-27 | |
| 2018-12-31 | -$7.40M 10-K · filed 2019-03-22 | |
| 2017-12-31 | -$1.00M 10-K · filed 2019-03-22 | |
| 2016-12-31 | -$15.70M 10-K · filed 2018-03-15 | -$9.20M 10-K · filed 2017-03-16 |
| 2015-12-31 | $11.80M 10-K · filed 2017-03-16 | $11.79M 10-K · filed 2016-03-10 |
| 2014-12-31 | $7.71M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |